
NMIBC Guideline Update for Urologists: What's Changed and Why it Matters
11/11/2026
0:00
1:13:40
NMIBC Guideline Update for Urologists: What's Changed and Why it Matters
CME Available: https://cme.auanet.org/URL/NMIBCURO261ONL
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Evaluate emerging clinical trial data and updates to AUA/SUO NMIBC guidelines in the context of high recurrence and complication rates in order to incorporate evidence- based adjustments into current treatment paradigms.
2. Apply guideline-directed risk stratification tools to identify and select appropriate patients with high-risk NMIBC, in order to personalize therapy selection and sequencing.
3. Integrate best practices for the safe and effective use of novel intravesical and systemic immunotherapies into NMIBC care pathways, with an emphasis on collaboration between urology and medical oncology to optimize shared decision-making.
4. Implement patient-centered strategies to reduce disease recurrence and mitigate treatment-related adverse events.
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
- AstraZeneca
- Immunity Bio, Inc
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Urogen, Inc.
More episodes from "AUAUniversity"



Don't miss an episode of “AUAUniversity” and subscribe to it in the GetPodcast app.








